Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 4/20 | 0.38 |
| ▸ | RXRB | P28702 | 3/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
| ▸ | USP19 | O94966 | 1/20 | 0.37 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8607286 | 0.90 | PTGS1 (0.40) | PTGS1PTGS2NR4A2CA9RXRA | |
| SCHEMBL8556142 | 0.85 | PTGS2 (0.46) | PTGS1PTGS2NR4A2CA9RXRA | |
| SCHEMBL6308687 | 0.84 | NR4A2 (0.44) | PTGS1PTGS2NR4A2CA9RXRA | |
| SCHEMBL6860698 | 0.83 | PTGS2 (0.59) | PTGS1PTGS2NR4A2CA9 | |
| SCHEMBL8558402 | 0.83 | PTGS2 (0.44) | PTGS1PTGS2NR4A2RXRARXRB | |
| SCHEMBL6308385 | 0.83 | PTGS1 (0.41) | PTGS1PTGS2NR4A2CA9RXRA | |
| SCHEMBL8561129 | 0.81 | PTGS2 (0.44) | PTGS1PTGS2NR4A2CA9RXRA | |
| SCHEMBL8558731 | 0.81 | PTGS2 (0.47) | PTGS1PTGS2NR4A2RXRARXRB | |
| SCHEMBL8558075 | 0.80 | PTGS2 (0.43) | PTGS1PTGS2NR4A2RXRARXRB | |
| SCHEMBL8604310 | 0.80 | RXRA (0.43) | NR4A2CA9RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248943-A9 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-20030073722-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248943-A9 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS1 9/4885PTGS2 5/4885NR4A2 1141/4885 |
| US-20030073722-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | PTGS1 9/4885PTGS2 5/4885NR4A2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.